Luas Diagnostics launches 15-minute Covid-19 Immune Status Test in the UK and Ireland

              Luas Diagnostics launches 15-minute Covid-19 Immune Status Test in the UK and Ireland.

 

Luas Diagnostics of Guildford, Surrey, today announced the launch of a test to determine immunity to Covid-19 post infection or vaccination.

 

The product, which is manufactured by Chembio Diagnostics Systems of New York, uses a fingerstick of blood for the detection, differentiation and quantification of IgM and IgG receptor binding domain antibodies to SARS-CoV-2. The results are read and stored in a portable reader which provides semi-quantitative results in either laboratory or remote settings. The total time to result is 15 minutes and the antibody response is represented numerically.

 

William James, Professor of Virology at the Sir William Dunn School of Pathology at the University of Oxford stated:

 

Antibodies in the blood, induced either by SARS-CoV-2 infection or, even more importantly, by vaccination, are critical in protecting people from future infection and severe Covid19 disease. It is clear that the higher the concentration of specific, anti-SARS-CoV-2 antibody in the blood, the higher the level of protection. We now know that immunization with the approved vaccines generates high levels of antibody that provide good levels of protection against infection. This is why we recommend everyone who can, should get vaccinated at the earliest opportunity, and why it is so important to make vaccines available across the world.

 

“The availability of a simple and rapid blood test that can quantify antibody levels is therefore an important factor in monitoring the likely level of immune protection in both convalescent individuals and vaccinees and could be useful in decisions on whether and when to give booster jabs. Being able to distinguish the IgM from the IgG class of antibody response will also provide potentially useful information about the stage of a person’s immune response, and its likely persistence over time”

 

Brendan Farrell, CEO of Luas Diagnostics, commented: “We are excited to form a partnership with Chembio to market their test to determine antibody response post infection or vaccination. A recent study has shown that 10-15% of people, particularly among the higher age group, may not produce antibodies even after the second dose of vaccine and thus may have limited protection against the virus.”

 

www.luasdiagnostics.com /

ends

 

 

 

Notes to editors

 

About Luas Diagnostics

 

Luas Diagnostics is based in Guildford, Surrey and is a UK registered private company, which was founded in 2020.

 

Luas is specialised in the development, manufacture and marketing of rapid tests which can be used Point-of-Care and which are e-health enabled. The focus of our R+D is on the development of rapid, quantitative tests to determine the levels of therapeutic drugs in a patients’ blood using a hand-held reader which transmits the results to a secure cloud for access by physicians.

In addition, we are the exclusive distributor in the UK and Ireland of the Chembio Diagnostic Systems Point-of-care products for infectious diseases

www.luasdiagnostics.com /

 

About Chembio Diagnostic Systems

Chembio Diagnostics Systems of Hauppauge New York is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 15-20 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners.

 

The DPP Covid-19 IgM/IgG test, which is CE marked, uses fingerstick whole blood to produce a result in 15 minutes and separately and simultaneously detects both the IgM and IgG antibodies to Sars-CoV-2, thus providing a result showing whether the patient has been infected and whether it is a current or past infection.

 

Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Other products in the Chembio portfolio include Point-of-Care tests for HIV (oral fluid and blood), Syphilis, Zika virus and Ebola.

 

For further information and images, please contact :

johnstarr@clareville.co.uk

tel 07860 200934

Share this story

Share on email
Email
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn